Table 3.
Risk of adverse clinical outcomes among very young ACS patients stratified by age.
| No./Total No. (%) |
Unadjusted RR (95% CI) | P-value | Adjusted∗ RR (95% CI) | P-value | ||
|---|---|---|---|---|---|---|
| Young (Age ≤50) |
Older (Age >50) (n = 16, 612) | |||||
| (n = 4762) | ||||||
| In-hospital Outcomes | ||||||
| MACE | 91 (1.9%) | 744 (4.5%) | 0.43 (0.34–0.53) | <0.001 | 0.49 (0.40–0.61) | <0.001 |
| Death | 66 (1.4%) | 586 (3.5%) | 0.39 (0.30–0.51) | <0.001 | 0.46 (0.36–0.59) | <0.001 |
| Reinfarction | 27 (0.6%) | 140 (0.8%) | 0.67 (0.45–1.02) | 0.059 | 0.71 (0.51–1.00) | 0.05 |
| Blood transfusion | 21 (0.4%) | 214 (1.3%) | 0.34 (0.22–0.54) | <0.001 | 0.50 (0.33–0.76) | <0.001 |
| Stroke | 9 (0.2%) | 84 (0.5%) | 0.37 (0.19–0.74) | 0.005 | 0.45 (0.25–0.84) | 0.01 |
| Heart failure | 216 (4.5%) | 1249 (7.5%) | 0.60 (0.52–0.70) | <0.001 | 0.71 (0.62–0.80) | <0.001 |
| Cardiac arrest | 78 (1.6%) | 579 (3.5%) | 0.47 (0.37–0.60) | <0.001 | 0.53 (0.42–0.66) | <0.001 |
| Major bleeding | 3 (0.1%) | 24 (0.1%) | 0.44 (0.13–1.45) | 0.175 | 0.48 (0.14–1.65) | 0.24 |
| 30-day Outcomes | ||||||
| MACE | 147 (3.1%) | 1100 (6.7%) | 0.47 (0.39–0.55) | <0.001 | 0.54 (0.46–0.64) | <0.001 |
| Death | 96 (2.0%) | 858 (5.2%) | 0.39 (0.32–0.48) | <0.001 | 0.46 (0.38–0.56) | <0.001 |
| CVD death | 94 (2.0%) | 834 (5.1%) | 0.39 (0.32–0.49) | <0.001 | 0.46 (0.38–0.57) | <0.001 |
| Reinfarction | 44 (0.9%) | 212 (1.3%) | 0.72 (0.52–1.00) | 0.051 | 0.78 (0.58–1.04) | 0.095 |
RR = Relative risk from multivariate regression, multi-level analysis for women compared to men.
MACE included a composite of death, reinfarction, major bleeding and stroke.
Models adjusted for sex, smoking, diabetes, hypertension, cardiac status (STEMI vs. NSTEMI), and PCI with random intercepts for centers.
Abbreviation: MACE, major adverse cardiac endpoint; CVD, cardiovascular disease.